Last reviewed · How we verify
NCT03863535
PRP vs PRP+IVC for Severe nPDR
NA trial testing Conbercept in Severe Nonproliferative Diabetic Retinopathy in 40 participants. Status unknown.
1 January 2021
Quick facts
| Lead sponsor | Ruijin Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 18 January 2019 |
| Primary completion | 1 January 2021 |
| Estimated completion | 30 September 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- Conbercept — full drug profile →
- Panretinal coagulation
Conditions studied
- Severe Nonproliferative Diabetic Retinopathy — all drugs for Severe Nonproliferative Diabetic Retinopathy →
- Diabetic Retinopathy — all drugs for Diabetic Retinopathy →
- Diabete Mellitus — all drugs for Diabete Mellitus →
Sponsor
Ruijin Hospital
Who can join
18 and older, any sex, with Severe Nonproliferative Diabetic Retinopathy or Diabetic Retinopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The randomized clinical trial aims to compare the therapeutic effects between panretinal photocoagulation(PRP) and PRP combined with intravitreal conbercept (IVC) injection in severe nPDR with/without diabetic macular edema patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03863535
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Conbercept
Trials testing the same drug.
- NCT06717412 — Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy · NA · recruiting
- NCT06305143 — Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic Retinopathy · Phase 4 · active not recruiting
- NCT05222633 — Anti-VEGF in Real-world · unknown
- NCT04782115 — Evaluation of RC28-E Injection in Diabetic Macular Edema · Phase 2 · completed
- NCT04627402 — Effects of Adding Triamcinolone Acetonide to Conbercept Treatment for Refractory Diabetic Macular Edema (CONTE) · NA · unknown
Other Ruijin Hospital trials
Trials by the same sponsor.
- NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
- NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
- NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
- NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
- NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03863535 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
- Last refreshed: 5 March 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03863535.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing